Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | EVP, Finance & Administration | June 26, 2019 | June 28, 2019 |
| GRAIL, Inc.GRAL · Entity 4122 | Director | July 15, 2026 | July 16, 2026 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date June 26, 2019 · Filed June 28, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 169,552 |
Reported balance
After 2019-06-26 transaction · row 1
1 source rowRow 1 · 2019-06-26 · Purchase · Acquired 30,400 · Balance 169,552 |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy spouse | 501 |
Reported balance
Holding disclosure · report date 2019-06-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 501 F1: The reporting person disclaims beneficial ownership of all securities held by his spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person disclaims beneficial ownership of all securities held by his spouse.
GRAIL, Inc.
Report date July 15, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,978 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 276 · Balance 42,978 F1: Represents 276 deferred stock units granted to Mr. Chase under our deferred stock program and 2024 Equity Incentive Plan in lieu of $20,568.49 of cash fees payable to Mr. Chase for his service as a director, based on a price per share of $74.36, which was the closing price per share of the Company's common stock on July 15, 2026. The awards will vest immediately upon grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 276 deferred stock units granted to Mr. Chase under our deferred stock program and 2024 Equity Incentive Plan in lieu of $20,568.49 of cash fees payable to Mr. Chase for his service as a director, based on a price per share of $74.36, which was the closing price per share of the Company's common stock on July 15, 2026. The awards will vest immediately upon grant date.
Intellia Therapeutics, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 143,893 |
Reported balance
After 2026-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 9,200 · Balance 143,893 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.89 · Expires 2036-06-08 | Direct | 13,300 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 13,300 · Balance 13,300 F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2017 Filed Feb 21, 2017 22:50 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 35,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002805 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,810 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017. Read SEC document |
| December 02, 2016 Filed Dec 2, 2016 22:08 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 6,600 | $0.00 Strike: $27.29 | $0.00 |
DisclosureSEC source: 0001179110-16-032340 · edgar.xml · derivative · entry 4 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 6,600 shares Expires 2017-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2016 Filed Dec 2, 2016 22:08 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 6,600 | $59.19 | $390,654.00 |
DisclosureSEC source: 0001179110-16-032340 · edgar.xml · nonDerivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,370 Read SEC document |
| December 02, 2016 Filed Dec 2, 2016 22:08 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 6,600 | $27.29 | $180,114.00 |
DisclosureSEC source: 0001179110-16-032340 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 22:19 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 45,658 | $56.00 | $2,556,848.00 |
DisclosureSEC source: 0001179110-16-020677 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,370 Read SEC document |
| February 18, 2016 Filed Feb 22, 2016 22:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 95,400 | $0.00 Strike: $54.86 | $0.00 |
DisclosureSEC source: 0001179110-16-019778 · edgar.xml · derivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,400 Underlying: Common stock · 95,400 shares Expires 2026-02-17 F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 31,800 on 02/18/2017, 31,800 on 02/18/2018, and 31,800 on 02/18/2019. Read SEC document |
| February 28, 2015 Filed Mar 3, 2015 23:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 8,192 | $60.50 | $495,616.00 |
DisclosureSEC source: 0001179110-15-004094 · edgar.xml · nonDerivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,028 Read SEC document |
| February 27, 2015 Filed Mar 3, 2015 23:05 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 10,299 | $60.52 | $623,295.48 |
DisclosureSEC source: 0001179110-15-004094 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,220 Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:08 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 110,770 | $0.00 Strike: $58.88 | $0.00 |
DisclosureSEC source: 0001179110-15-003161 · edgar.xml · derivative · entry 3 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,770 Underlying: Common stock · 110,770 shares Expires 2025-02-18 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 36,924 on 02/19/2016, 36,923 on 02/19/2017, and 36,923 on 02/18/2018 Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:08 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 56,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003161 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,519 F1 · shares: These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. F2 · balance_after: The amount of securities beneficially owned by the reporting person includes an additional 411 shares of AbbVie stock. Read SEC document |
| December 22, 2014 Filed Dec 22, 2014 22:22 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 8,495 | $0.00 Strike: $24.07 | $0.00 |
DisclosureSEC source: 0001179110-14-018635 · edgar.xml · derivative · entry 4 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 8,495 shares Expires 2015-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2014 Filed Dec 22, 2014 22:22 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 8,495 | $68.00 | $577,660.00 |
DisclosureSEC source: 0001179110-14-018635 · edgar.xml · nonDerivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,068 Read SEC document |
| December 22, 2014 Filed Dec 22, 2014 22:22 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 8,495 | $24.07 | $204,500.98 |
DisclosureSEC source: 0001179110-14-018635 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:12 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 100 | $51.20 | $5,119.50 |
DisclosureSEC source: 0001179110-14-004329 · edgar.xml · nonDerivative · entry 4 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,068 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:12 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 1,400 | $50.19 | $70,271.60 |
DisclosureSEC source: 0001179110-14-004329 · edgar.xml · nonDerivative · entry 3 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,168 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:12 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 2,448 | $50.19 | $122,867.57 |
DisclosureSEC source: 0001179110-14-004329 · edgar.xml · nonDerivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,568 Read SEC document |
| February 28, 2014 Filed Mar 4, 2014 22:12 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 9,873 | $51.91 | $512,507.43 |
DisclosureSEC source: 0001179110-14-004329 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,016 Read SEC document |
| February 20, 2014 Filed Feb 24, 2014 22:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 92,740 | $0.00 Strike: $51.42 | $0.00 |
DisclosureSEC source: 0001179110-14-003467 · edgar.xml · derivative · entry 3 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,740 Underlying: Common stock · 92,740 shares Expires 2024-02-19 F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 30,914 on 02/20/2015, 30,913 on 02/20/2016, and 30,913 on 02/20/2017. Read SEC document |
| February 20, 2014 Filed Feb 24, 2014 22:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 53,770 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-003467 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,889 F1 · shares: These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| December 19, 2013 Filed Dec 21, 2013 01:32 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 3,438 | $0.00 Strike: $35.99 | $0.00 |
DisclosureSEC source: 0001179110-13-018461 · edgar.xml · derivative · entry 10 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,438 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2013 Filed Dec 21, 2013 01:32 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 1,591 | $0.00 Strike: $35.24 | $0.00 |
DisclosureSEC source: 0001179110-13-018461 · edgar.xml · derivative · entry 9 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,591 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2013 Filed Dec 21, 2013 01:32 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 1,620 | $0.00 Strike: $34.49 | $0.00 |
DisclosureSEC source: 0001179110-13-018461 · edgar.xml · derivative · entry 8 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,620 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2013 Filed Dec 21, 2013 01:32 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 963 | $0.00 Strike: $28.97 | $0.00 |
DisclosureSEC source: 0001179110-13-018461 · edgar.xml · derivative · entry 7 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 963 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2013 Filed Dec 21, 2013 01:32 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 6,149 | $54.32 | $334,013.68 |
DisclosureSEC source: 0001179110-13-018461 · edgar.xml · nonDerivative · entry 5 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,119 Read SEC document |
| December 19, 2013 Filed Dec 21, 2013 01:32 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 3,438 | $35.99 | $123,716.43 |
DisclosureSEC source: 0001179110-13-018461 · edgar.xml · nonDerivative · entry 4 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2013 Filed Dec 21, 2013 01:32 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 1,591 | $35.24 | $56,070.18 |
DisclosureSEC source: 0001179110-13-018461 · edgar.xml · nonDerivative · entry 3 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2013 Filed Dec 21, 2013 01:32 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 1,620 | $34.49 | $55,872.02 |
DisclosureSEC source: 0001179110-13-018461 · edgar.xml · nonDerivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2013 Filed Dec 21, 2013 01:32 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 963 | $28.97 | $27,894.93 |
DisclosureSEC source: 0001179110-13-018461 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 22:09 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 5,260 | $36.73 | $193,199.80 |
DisclosureSEC source: 0001179110-13-004014 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,656 Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 00:06 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 2,912 | $37.58 | $109,432.96 |
DisclosureSEC source: 0001179110-13-003030 · edgar.xml · nonDerivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,916 Read SEC document |
| February 14, 2013 Filed Feb 20, 2013 00:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 115,830 | $0.00 Strike: $35.88 | $0.00 |
DisclosureSEC source: 0001179110-13-003030 · edgar.xml · derivative · entry 4 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,830 Underlying: Common stock · 115,830 shares Expires 2023-02-13 F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 38,610 on 02/14/2014, 38,610 on 02/14/2015, and 38,610 on 02/14/2016. Read SEC document |
| February 14, 2013 Filed Feb 20, 2013 00:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 56,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-003030 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,828 F1 · shares: These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 07, 2013 Filed Feb 8, 2013 22:04 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 2,177 | $0.00 Strike: $32.43 | $0.00 |
DisclosureSEC source: 0001179110-13-002287 · edgar.xml · derivative · entry 6 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,177 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2013 Filed Feb 8, 2013 22:04 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 2,390 | $0.00 Strike: $32.00 | $0.00 |
DisclosureSEC source: 0001179110-13-002287 · edgar.xml · derivative · entry 5 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,390 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2013 Filed Feb 8, 2013 22:04 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 4,188 | $37.14 | $155,542.32 |
DisclosureSEC source: 0001179110-13-002287 · edgar.xml · nonDerivative · entry 3 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,128 Read SEC document |
| February 07, 2013 Filed Feb 8, 2013 22:04 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 2,177 | $32.43 | $70,592.49 |
DisclosureSEC source: 0001179110-13-002287 · edgar.xml · nonDerivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2013 Filed Feb 8, 2013 22:04 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 2,390 | $32.00 | $76,481.20 |
DisclosureSEC source: 0001179110-13-002287 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.